Xbrane Biopharma

Xbrane Biopharma EBITDA per Share

The EBITDA per Share of Xbrane Biopharma (XBRANE.ST) as of Oct 17, 2026 is -0.16 SEK. In the previous year, EBITDA per Share was -17.81 SEK — a change of -99.13% (higher).

EBITDA per Share

-0.16SEK

YoY

-99.13%

Last updated:

EBITDA per Share of Xbrane Biopharma is 2025 -0.16 SEK. EBITDA per Share of Xbrane Biopharma was 2024 -17.81 SEK. It decreases by -99.13% higher compared to the previous year.

The Xbrane Biopharma EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-24.86 SEK
Jan 1, 2019
-175.35 SEK
Jan 1, 2020
-158.36 SEK
Jan 1, 2021
-105.23 SEK
Jan 1, 2022
-87.18 SEK
Jan 1, 2023
-147.58 SEK
Jan 1, 2024
-17.81 SEK
Jan 1, 2025
-0.16 SEK
The Xbrane Biopharma EBITDA per Share history
YEAREBITDA per ShareYoY
-0.16SEK-99.13%
-17.81SEK-87.93%
-147.58SEK+69.28%
-87.18SEK-17.16%
-105.23SEK-33.55%
-158.36SEK-9.69%
-175.35SEK+605.46%
-24.86SEK-76.48%
-105.69SEK+11.83%
-94.51SEK+36.91%
-69.03SEK+345.18%
-15.51SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Xbrane Biopharma Stock analysis

What does Xbrane Biopharma do? Xbrane Biopharma AB, based in Solna, Sweden, operates in the Health Care sector as a biotechnology company specializing in the development and manufacturing of biosimilars. The company employs 92 full-time staff and focuses on injectable slow-release drugs and high-yield protein expression technology. Key products include Sperotide, a biosimilar to Decapeptyl, Trelstar, and Pamorelin, and Xlucane, a biosimilar to Lucentis, both developed for injectable use. Xbrane Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Xbrane Biopharma stock

EBITDA per Share of Xbrane Biopharma is -0.16 SEK in 2025.

EBITDA per Share of Xbrane Biopharma changed from -17.81 SEK to -0.16 SEK, representing a -99.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Xbrane Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Xbrane Biopharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Xbrane Biopharma